Active Ingredient History
Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. Esmolol predominantly blocks the beta-1 receptors in cardiac tissue. Used for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Tachycardia, Sinus (approved 1986)
Tachycardia, Supraventricular (approved 1986)
Acute Coronary Syndrome (Phase 4)
Aged (Phase 2)
Aging (Early Phase 1)
Anesthesia (Phase 4)
Anesthesia and Analgesia (Phase 4)
Angina Pectoris (Phase 4)
Atrial Fibrillation (Phase 2)
Blood Pressure (Phase 2)
Brain Injuries, Traumatic (Phase 1/Phase 2)
Brain Neoplasms (Phase 3)
Cardiomyopathy, Hypertrophic (Phase 4)
Cardiovascular Diseases (Phase 2)
Cerebral Arterial Diseases (Phase 3)
Cognitive Dysfunction (Phase 1/Phase 2)
Constipation (Phase 4)
Coronary Artery Disease (Phase 4)
Diabetic Foot (Phase 3)
Drug Overdose (Phase 4)
Gallstones (Phase 4)
General Surgery (Phase 3)
Healthy Volunteers (Phase 2)
Heart Diseases (Phase 4)
Heart Rate (Phase 2)
Hemodynamics (Phase 4)
Hemorrhagic Stroke (Phase 4)
Hypertension (Phase 4)
Hypotension (Phase 2)
Intracranial Aneurysm (Phase 3)
Intraoperative Awareness (Phase 4)
Intubation (Phase 4)
Ischemic Stroke (Phase 3)
Laminectomy (Phase 4)
Laparoscopy (Phase 4)
Lumbar Vertebrae (Phase 2)
Multiple Trauma (Phase 2)
Myocardial Ischemia (Phase 4)
Myocardial Reperfusion Injury (Phase 1/Phase 2)
Nasal Septal Perforation (Phase 4)
Nausea (Phase 4)
Ovarian Cysts (Phase 1/Phase 2)
Oxygen (Phase 4)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Peripheral Arterial Disease (Early Phase 1)
Pharmacokinetics (Phase 2)
Primary Dysautonomias (Phase 1/Phase 2)
Reflex, Abnormal (Phase 4)
Shock, Cardiogenic (Phase 4)
Shock, Septic (Phase 3)
Sinusitis (Phase 2)
Tachycardia (Phase 4)
Thoracic Surgery (Phase 4)
Tinnitus (Phase 4)
Tuberculosis (Phase 4)
Vascular Diseases (Phase 4)
Vomiting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
